Найти книгу: "Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors"

Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.

A book to cover developments in corrosion inhibitors is long overdue. This has been addressed by Dr Sastri in a book which presents fundamental aspects of corrosion inhibition, historical developments and the industrial applications of inhibitors. The book deals with the electrochemical principles and chemical aspects of corrosion inhibition, such as stability of metal complexes, the Hammett equation, hard and soft acid and base principle, quantum chemical aspects and Hansch' s model and also with the various surface analysis techniques, e.g. XPS, Auger, SIMS and Raman spectroscopy, that are used in industry for corrosion inhibition. The applications of corrosion inhibition are wide ranging. Examples given in this book include: oil and gas wells, petrochemical plants, steel reinforced cement, water cooling systems, and many more. The final chapters discuss economic and environmental considerations which are now of prime importance. The book is written for researchers in academia and industry, practicing corrosion engineers and students of materials science, engineering and applied chemistry.

Protein kinases play a critical role in cellular processes that impact overall organismal health and function. Of the kinases that collectively make up the Human Kinome, CK2 has garnered special attention because of its significant role in the generation of the human phosphoproteome. The role CK2 plays in the development of cancer and other disease has also made it of significant interest for its potential role in future therapeutics. Protein Kinase CK2 comprehensively brings together the varied work being done on this critical enzyme. Protein Kinase CK2 is logically divided into three sections. The first section reviews key molecular and structural aspects of the enzyme. The second section looks at functional aspects of CK2 and the diverse roles it plays in cellular development, function, and health. The final section focuses on CK2 and cancer, looking at the impacts of the kinase on neoplastic development and its rapidly developing role as a therapeutic agent. With contributions from the world’s leading experts in the field, Protein Kinase CK2 will serve as an invaluable guide to the expanding and vibrant body of research being performed on this enzyme. This will be an essential volume for anyone working in the fields of biochemistry, protein science, signal transduction, metabolic regulation, and cancer biology and therapeutics. Editor Lorenzo A. Pinna is Professor in the Department of Biomedical Sciences at the University of Padua, Padua, Italy. Also Published in the Wiley-IUBMB Series on Biochemistry and Molecular Biology: Plant Phenolics and Human Health: Biochemistry, Nutrition, and Pharmacology Edited by Cesar G. Fraga ISBN: 978-0-470-28721-7

This timely guide to kinase inhibitor drug development is the first to cover the entire drug pipeline, from target identification to compound development and clinical application. Edited by the pioneers in the field, on the drug development side this ready reference discusses classical medicinal chemistry approaches as well as current chemical genomics strategies. On the clinical side, both current and future therapeutic application areas for kinase inhibitor drugs are addressed, with a strong focus on oncology drugs. Backed by recent clinical experience with first-generation drugs in the battle against various forms of cancer, this is crucial reading for medicinal, pharmaceutical and biochemists, molecular biologists, and oncologists, as well as those working in the pharmaceutical industry.

Offers essential guidance for discovering and optimizing novel drug therapies Using detailed examples, Evaluation of Enzyme Inhibitors in Drug Discovery equips researchers with the tools needed to apply the science of enzymology and biochemistry to the discovery, optimization, and preclinical development of drugs that work by inhibiting specific enzyme targets. Readers will applaud this book for its clear and practical presentations, including its expert advice on best practices to follow and pitfalls to avoid. This Second Edition brings the book thoroughly up to date with the latest research findings and practices. Updates explore additional forms of enzyme inhibition and special treatments for enzymes that act on macromolecular substrates. Readers will also find new discussions detailing the development and application of the concept of drug-target residence time. Evaluation of Enzyme Inhibitors in Drug Discovery begins by explaining why enzymes are such important drug targets and then examines enzyme reaction mechanisms. The book covers: Reversible modes of inhibitor interactions with enzymes Assay considerations for compound library screening Lead optimization and structure-activity relationships for reversible inhibitors Slow binding and tight binding inhibitors Drug-target residence time Irreversible enzyme inactivators The book ends with a new chapter exploring the application of quantitative biochemical principles to the pharmacologic evaluation of drug candidates during lead optimization and preclinical development. The Second Edition of Evaluation of Enzyme Inhibitors in Drug Discovery continues to offer a treatment of enzymology applied to drug discovery that is quantitative and mathematically rigorous. At the same time, the clear and simple presentations demystify the complex science of enzymology, making the book accessible to many fields— from pharmacology to medicinal chemistry to biophysics to clinical medicine.

Edited by an orthopaedic surgeon and a haematologist who are leading specialists in the treatment of haemophilia, Inhibitors in Patients with Haemophilia reviews the different haemostatic products and protocols for the control of bleeding and surgery in haemophilic patients with inhibitors. The book draws together in a single volume all of the clinical issues involved in the treatment of inhibitors from numerous specialists worldwide. It will be an invaluable resource for all those treating inhibitors in people with haemophilia.